Bone Marrow Transplantation for Myelodysplastic Syndrome
Allogeneic hematopoietic stem cell transplantation (HSCT) is strongly recommended for higher-risk MDS patients (<70 years without major comorbidities) and should be considered at diagnosis, as it represents the only potentially curative treatment option. 1, 2
Risk Stratification to Determine Transplant Eligibility
The decision for bone marrow transplantation in MDS should be based primarily on disease risk stratification using the Revised International Prognostic Scoring System (IPSS-R):
Higher-Risk MDS (IPSS-R High/Very High)
- Primary recommendation: Proceed to allogeneic HSCT if patient is:
- Median survival without transplant: <3 years 2
- Consider hypomethylating agents (azacitidine or decitabine) as a bridge to transplantation 4, 1
- Cytoreductive therapy recommended prior to transplant if bone marrow blasts ≥10% 3
Lower-Risk MDS (IPSS-R Very Low, Low, Some Intermediate)
- Consider HSCT only after failure of conventional therapies or disease progression 5
- Transplant may be considered for selected patients with severe cytopenias despite appropriate non-transplant therapies 4
- 3-year survival rates with HSCT: 65-70% with HLA-identical related or unrelated donors 5
Donor Selection
Standard donors (in order of preference) 3:
- HLA-identical siblings
- Syngeneic donors
- 8/8 or 10/10 matched unrelated donors (MUDs)
Alternative donors should be considered for higher-risk patients when no matched donor is available within a reasonable timeframe 3
Consider donor characteristics including age, sex, and cytomegalovirus (CMV) status during selection 3
Pre-Transplant Considerations
Cytoreduction Before Transplant
- For patients with ≥10% bone marrow blasts, cytoreduction is recommended before starting conditioning 3, 1
- Options include:
- Hypomethylating agents (HMAs): azacitidine or decitabine
- Intensive chemotherapy (for younger patients with favorable cytogenetics) 5
Timing of Transplant
- For higher-risk MDS: proceed to transplant as soon as a donor is identified 1, 2
- After failure of hypomethylating agents: proceed directly to HSCT as median survival after HMA failure is <6 months 3
- After failure of intensive chemotherapy: if relapse occurs within 1 year of CR1, proceed directly to HSCT; if relapse occurs after prolonged CR1 (>1 year), consider remission induction with ICT to achieve CR2 before HSCT 3
Conditioning Regimens
- Standard myeloablative conditioning: Preferred for younger, fit patients
- Reduced-intensity conditioning: Consider for older patients (60-70 years) or those with comorbidities 5, 6
Post-Transplant Challenges
- Disease relapse remains a major challenge (10-40% probability) 5
- Graft-versus-host disease (both acute and chronic) requires careful management 6
Common Pitfalls to Avoid
- Delayed referral: Patients with higher-risk MDS should be referred for transplant evaluation at diagnosis
- Excessive cytoreduction attempts: Multiple failed cycles of chemotherapy can increase comorbidities and reduce transplant success
- Overlooking iron overload: Patients with significant transfusion burden should receive iron chelation before transplant 1
- Ignoring molecular markers: TP53, EZH2, and ETV6 mutations are associated with poor prognosis and may influence transplant timing 5
Allogeneic HSCT remains the only potentially curative option for MDS, with the decision to transplant requiring careful consideration of disease risk, patient factors, and donor availability.